GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofrontera AG (XTER:B8FK) » Definitions » Additional Paid-In Capital

Biofrontera AG (XTER:B8FK) Additional Paid-In Capital : €137.33 Mil(As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Biofrontera AG Additional Paid-In Capital?


Biofrontera AG's quarterly additional paid-in capital declined from Jun. 2023 (€137.19 Mil) to Sep. 2023 (€137.16 Mil) but then increased from Sep. 2023 (€137.16 Mil) to Dec. 2023 (€137.33 Mil).

Biofrontera AG's annual additional paid-in capital declined from Dec. 2021 (€137.33 Mil) to Dec. 2022 (€137.32 Mil) but then increased from Dec. 2022 (€137.32 Mil) to Dec. 2023 (€137.33 Mil).

Biofrontera AG Additional Paid-In Capital Historical Data

The historical data trend for Biofrontera AG's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biofrontera AG Additional Paid-In Capital Chart

Biofrontera AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 123.49 137.33 137.32 137.33

Biofrontera AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 137.32 137.33 137.19 137.16 137.33

Biofrontera AG Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Biofrontera AG Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Biofrontera AG's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Biofrontera AG (XTER:B8FK) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofrontera AG (XTER:B8FK) » Definitions » Additional Paid-In Capital
Comparable Companies
XTER:PA8 XTER:HAEK ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692 NSE:DIVISLAB BOM:500124 VTRS NBIX SZSE:000963 SHSE:600085 XPAR:IPN SHSE:600196
Traded in Other Exchanges
B8F:Germany B8F:Germany B8F:Germany
Address
Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377
Website
https://www.biofrontera.com
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.

Biofrontera AG (XTER:B8FK) Headlines

No Headlines